Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
Identifieur interne : 000B41 ( Ncbi/Merge ); précédent : 000B40; suivant : 000B42Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
Auteurs : B. Custer [États-Unis] ; M P Janssen [Pays-Bas] ; G. Hubben [Allemagne] ; M. Vermeulen [Afrique du Sud] ; M. Van Hulst [Pays-Bas]Source :
- Vox sanguinis [ 1423-0410 ] ; 2017.
Abstract
Most countries test donations for HIV, HCV and HBV using serology with or without nucleic acid testing (NAT). Cost-utility analyses provide information on the relative value of different screening options. The aim of this project was to develop an open access risk assessment and cost-utility analysis web-tool for assessing HIV, HCV and HBV screening options (http://www.isbtweb.org/working-parties/transfusion-transmitted-infectious-diseases/). An analysis for six countries (Brazil, Ghana, the Netherlands, South Africa, Thailand and USA) was conducted.
DOI: 10.1111/vox.12538
PubMed: 28597489
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000508
- to stream PubMed, to step Curation: 000508
- to stream PubMed, to step Checkpoint: 000508
Links to Exploration step
pubmed:28597489Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.</title><author><name sortKey="Custer, B" sort="Custer, B" uniqKey="Custer B" first="B" last="Custer">B. Custer</name><affiliation wicri:level="2"><nlm:affiliation>Blood Systems Research Institute, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood Systems Research Institute, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Janssen, M P" sort="Janssen, M P" uniqKey="Janssen M" first="M P" last="Janssen">M P Janssen</name><affiliation wicri:level="3"><nlm:affiliation>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Hubben, G" sort="Hubben, G" uniqKey="Hubben G" first="G" last="Hubben">G. Hubben</name><affiliation wicri:level="3"><nlm:affiliation>BaseCase, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>BaseCase, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Vermeulen, M" sort="Vermeulen, M" uniqKey="Vermeulen M" first="M" last="Vermeulen">M. Vermeulen</name><affiliation wicri:level="1"><nlm:affiliation>South African National Blood Service, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>South African National Blood Service, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Hulst, M" sort="Van Hulst, M" uniqKey="Van Hulst M" first="M" last="Van Hulst">M. Van Hulst</name><affiliation wicri:level="4"><nlm:affiliation>Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28597489</idno><idno type="pmid">28597489</idno><idno type="doi">10.1111/vox.12538</idno><idno type="wicri:Area/PubMed/Corpus">000508</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000508</idno><idno type="wicri:Area/PubMed/Curation">000508</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000508</idno><idno type="wicri:Area/PubMed/Checkpoint">000508</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000508</idno><idno type="wicri:Area/Ncbi/Merge">000B41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.</title><author><name sortKey="Custer, B" sort="Custer, B" uniqKey="Custer B" first="B" last="Custer">B. Custer</name><affiliation wicri:level="2"><nlm:affiliation>Blood Systems Research Institute, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood Systems Research Institute, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Janssen, M P" sort="Janssen, M P" uniqKey="Janssen M" first="M P" last="Janssen">M P Janssen</name><affiliation wicri:level="3"><nlm:affiliation>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Hubben, G" sort="Hubben, G" uniqKey="Hubben G" first="G" last="Hubben">G. Hubben</name><affiliation wicri:level="3"><nlm:affiliation>BaseCase, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>BaseCase, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Vermeulen, M" sort="Vermeulen, M" uniqKey="Vermeulen M" first="M" last="Vermeulen">M. Vermeulen</name><affiliation wicri:level="1"><nlm:affiliation>South African National Blood Service, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>South African National Blood Service, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Hulst, M" sort="Van Hulst, M" uniqKey="Van Hulst M" first="M" last="Van Hulst">M. Van Hulst</name><affiliation wicri:level="4"><nlm:affiliation>Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author></analytic><series><title level="j">Vox sanguinis</title><idno type="eISSN">1423-0410</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Most countries test donations for HIV, HCV and HBV using serology with or without nucleic acid testing (NAT). Cost-utility analyses provide information on the relative value of different screening options. The aim of this project was to develop an open access risk assessment and cost-utility analysis web-tool for assessing HIV, HCV and HBV screening options (http://www.isbtweb.org/working-parties/transfusion-transmitted-infectious-diseases/). An analysis for six countries (Brazil, Ghana, the Netherlands, South Africa, Thailand and USA) was conducted.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28597489</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>09</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0410</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vox sanguinis</Title><ISOAbbreviation>Vox Sang.</ISOAbbreviation></Journal><ArticleTitle>Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.</ArticleTitle><Pagination><MedlinePgn>526-534</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/vox.12538</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Most countries test donations for HIV, HCV and HBV using serology with or without nucleic acid testing (NAT). Cost-utility analyses provide information on the relative value of different screening options. The aim of this project was to develop an open access risk assessment and cost-utility analysis web-tool for assessing HIV, HCV and HBV screening options (http://www.isbtweb.org/working-parties/transfusion-transmitted-infectious-diseases/). An analysis for six countries (Brazil, Ghana, the Netherlands, South Africa, Thailand and USA) was conducted.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Four strategies; (1) antibody assays (Abs) for HIV and HCV + HBsAg, (2) antibody assays that include antigens for HIV and HCV (Combo) + HBsAg, (3) NAT in minipools of variable size (MP NAT) and (4) individual donation (ID) NAT can be evaluated using the tool. Country-specific data on donors, donation testing results, recipient outcomes and costs are entered using the online interface. Results obtained include the number infections interdicted using each screening options, and the (incremental and average) cost-utility of the options.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In each of the six countries evaluated, the use of antibody assays is cost effective or even cost saving. NAT has varying cost-utility depending on the setting, and where adopted, the incremental cost-utility exceeds any previously defined or proposed threshold in each country.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The web-tool allows an assessment of infectious units interdicted and value for money of different testing strategies. Regardless of gross national income (GNI) per capita, countries appear willing to dedicate healthcare resources to blood supply safety in excess of that for other sectors of health care.</AbstractText><CopyrightInformation>© 2017 International Society of Blood Transfusion.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Custer</LastName><ForeName>B</ForeName><Initials>B</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6251-366X</Identifier><AffiliationInfo><Affiliation>Blood Systems Research Institute, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>M P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1682-7817</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transfusion Technology Assessment Department, Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubben</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>BaseCase, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeulen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>South African National Blood Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hulst</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vox Sang</MedlineTA><NlmUniqueID>0413606</NlmUniqueID><ISSNLinking>0042-9007</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HBV</Keyword><Keyword MajorTopicYN="N">HCV</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">blood screening</Keyword><Keyword MajorTopicYN="N">cost-effectiveness analysis</Keyword><Keyword MajorTopicYN="N">cost-utility</Keyword><Keyword MajorTopicYN="N">methods</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28597489</ArticleId><ArticleId IdType="doi">10.1111/vox.12538</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li><li>Allemagne</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Berlin</li><li>Californie</li><li>Groningue (province)</li><li>Utrecht (province)</li></region><settlement><li>Berlin</li><li>Groningue</li><li>Utrecht</li></settlement><orgName><li>Université de Groningue</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Custer, B" sort="Custer, B" uniqKey="Custer B" first="B" last="Custer">B. Custer</name></region></country><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Janssen, M P" sort="Janssen, M P" uniqKey="Janssen M" first="M P" last="Janssen">M P Janssen</name></region><name sortKey="Van Hulst, M" sort="Van Hulst, M" uniqKey="Van Hulst M" first="M" last="Van Hulst">M. Van Hulst</name></country><country name="Allemagne"><region name="Berlin"><name sortKey="Hubben, G" sort="Hubben, G" uniqKey="Hubben G" first="G" last="Hubben">G. Hubben</name></region></country><country name="Afrique du Sud"><noRegion><name sortKey="Vermeulen, M" sort="Vermeulen, M" uniqKey="Vermeulen M" first="M" last="Vermeulen">M. Vermeulen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000B41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28597489
|texte= Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28597489" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |